To investigate the effects of D-002 (beeswax alcohols) on esophagitis induced by chronic gastroesophageal reflux (c-GER) in rats. Rats were randomized into a sham and five groups subjected to c-GER: a positive vehicle control, three D-002 (50, 100 and 200 mg/kg), and one omeprazole (20 mg/kg) group, all treated orally for seven days. cGER was induced by ligation of the junction between the forestomach and the duodenal side of the pylorus. Esophageal lesions index (ELI), esophageal malondialdehyde (MDA) and sulfhydril groups (SHG) concentrations were assessed. The positive control group exhibited macroscopically signs of esophageal injury assessed in term of ELI, which was significantly higher than in the negative control. D-002 (50, 100 and 200 mg/kg) reduced the ELI, showing 30.5, 72.9 and 76.4% protection, respectively; and also significantly attenuated the increased MDA (37.4, 63.6 and 94.2%, respectively) and SHG (16.6, 41.6 and 72.9%, respectively) esophageal concentrations versus the positive control. Omeprazole decreased the ELI (80.2%), MDA (99.3%) and SH (85.4%) esophageal concentrations. As conclusions, this study suggest that repeated oral administration with D-002 protects against reflux esophagitis and decreases esophageal lipid peroxidation and protein oxidation markers in rats with c-GER.
Key words: D-002, beeswax alcohols, esophagitis, chronic gastroesophageal reflux (cGER), oxidative stress, rats.
[1] A.F. Peery, E.S. Dellon, J. Lund, et al, Burden of gastrointestinal disease in the United States: 2012 update, Gastroenterology, 143, 2012, 1179-1187.
[2] G. Boeckxstaens, H.B. El-Serag, A.J. Smout, P.J. Kahrilas, Symptomatic reflux disease: the present, the past and the future, Gut, 7, 2014, doi: 10.1136/gutjnl-2013-306393.
[3] Y.W. Wu, P.H. Tseng, Y.C. Lee, et al, Association of esophageal inflammation, obesity and gastroesophageal reflux disease: From FDG PET/CT Perspective, PLoS One, 9(3), 2014, e920012014, doi: 10.1371/journal.pone.0092001. eCollection 2014
[4] J.H. Rubenstein, J.W. Chen, Epidemiology of gastroesophageal reflux disease, Gastroenterol Clin North Am, 43, 2014, 1-14. [5] N.J. Shaheen, J.E, Richter, Barrett's oesophagus, Lancet, 373, 2009, 850–861.
[6] G.N. Tytgat, Recent developments in gastroesophageal reflux disease and Barrett's esophagus: ANNO 2012, J Dig Dis, 13, 2012, 291-295.
[7] K. Tsuboi, M. Hoshino, A. Sundaram, F. Yano, S.K. Mittal, Role of the lower esophageal sphincter on esophageal acid exposure - a review of over 2000 patients, Trop Gastroenterol, 33, 2012,107-111.
[8] K. Nagahama, M. Yamoto, H. Nishio, K. Takeuchi, Essential role of pepsin in pathogenesis of acid reflux esophagitis in rats, Dig Dis Sci, 51, 2006, 303-306.